Completion of US-FDA Inspection at the Company''s flagship facility in Bangalore
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
USFDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at Strides Pharma's flagship Bangalore facility from May 12-20, 2026. The inspection concluded with the issuance of a Form 483 containing five observations, which are areas where the regulator has identified potential deviations from GMP standards. The company has stated it will respond to these observations within the prescribed timeframe and will update exchanges on any further developments.
Form 483 observations indicate potential compliance concerns that could affect the company's ability to supply products to the US market if not adequately addressed. While this is a routine inspection finding rather than an outright rejection, it introduces regulatory risk for shareholders and may require close monitoring of the company's response and FDA's acceptance of corrective actions.